Welgus Howard G.'s Form 4 filing
Arcutis Biotherapeutics, Inc. (ARQT) · filed Jun 17, 2026
- Accession no.
- 0001628280-26-044079
- Filed
- Jun 17, 2026
- Trade date
- Jun 15-17, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 5 non-derivative transactions and 3 derivative transactions. Open-market sales total $116.3K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Welgus Howard G.CIK 0001801050 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | Common Stock | MOption exerciseAcquired | +822 | $6.52 | +$5,359.44 | 39,200 | Direct | |
| Jun 15, 2026 | Common Stock | MOption exerciseAcquired | +1,019 | $7.51 | +$7,652.69 | 40,219 | Direct | |
| Jun 15, 2026 | Common Stock | MOption exerciseAcquired | +2,255 | $8.63 | +$19,460.65 | 42,474 | Direct | |
| Jun 15, 2026 | Common Stock | SSaleDisposed | −4,096 | $24.41 | −$99,983.36 | 38,378 | Direct | |
| Jun 17, 2026 | Common Stock | SSaleDisposed | −635 | $25.67 | −$16,300.45 | 37,743 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | Common Stock | MOption exerciseDisposed | −822 | $0.00 | $0 | 9,040 | Direct | |
| Jun 15, 2026 | Common Stock | MOption exerciseDisposed | −1,019 | $0.00 | $0 | 11,201 | Direct | |
| Jun 15, 2026 | Common Stock | MOption exerciseDisposed | −2,255 | $0.00 | $0 | 24,797 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.